Want to see QDEL full AI Analyst Report?
QDEL Stock Chart & Stats
$15.05
$0.78(4.86%)
At close: 4:00 PM EDT
$15.05
$0.78(4.86%)
Day’s Range― - ―
52-Week Range$9.92 - $35.58
Previous Close$16.9
Volume1.06M
Average Volume (3M)1.44M
Market Cap
$728.27M
Enterprise Value$3.89K
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 04, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume1,603,642
30 Day Avg. Volume1,438,902
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside-0.33% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.77
Revenue Forecast (FY)$2.54B
Bulls Say, Bears Say
Bulls Say
Ex-China GrowthGrowth across the company’s major franchises outside China demonstrates that core diagnostic demand remains resilient and geographically diversified. Continued expansion in laboratories, immunohematology, and point-of-care testing can support revenue durability while reducing reliance on any single market.
EBITDA And Margin ExpansionAdjusted EBITDA growth materially outpaced revenue growth, and higher margins indicate that cost controls and operating discipline are improving earnings conversion. If sustained, this progress can strengthen profitability, support investment in the portfolio, and improve the company’s ability to generate cash.
Lex/Neulixa CommercializationThe Lex acquisition adds a commercialization opportunity within respiratory diagnostics and is progressing beyond simple deal completion. Manufacturing preparation, customer engagement, and planned instrument placements could expand the installed base and create recurring utilization and consumables revenue over coming respiratory seasons.
Bears Say
Deep Profitability DeficitSeverely negative earnings show that gross profit is not currently covering the company’s operating cost structure. Without sustained improvement, ongoing losses can erode financial resilience, restrict strategic flexibility, and make future growth investments more dependent on external financing or substantial cost reductions.
Negative Cash GenerationNegative operating and free cash flow weaken the self-funding capacity of the business and increase the importance of working-capital control and execution. Persistent cash consumption could limit debt reduction, constrain investment in new platforms, and reduce flexibility during periods of softer testing demand.
China Pricing UncertaintyThe proposed pricing changes represent a regulatory and purchasing disruption rather than a normal seasonal fluctuation. Customer inventory reductions and slower purchases may persist while the guidelines evolve, creating pressure on revenue, geographic mix, margins, and the predictability of China’s contribution.
QuidelOrtho News
QDEL FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $9.92 and its highest was $35.58 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $728.27M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 43 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.179.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.2.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went down -24.724%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in QDEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$15.00 (-0.33% Downside)
$15.00 (-0.33% Downside)
Blogger Sentiment
Neutral
QDEL Sentiment 60%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 439.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL Company Deck
QDEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all QDEL earnings summariesQDEL Stock 12 Month Forecast
Average Price Target
$15.00
▼(-0.33% Downside)
Technical Analysis
Ownership Overview
0.89% Insiders
40.99% Mutual Funds
18.47% Other Institutional Investors
5.68% Public Companies and
Individual Investors